Heart, Lung and Circulation
Volume 19, Issue 4 , Pages 225-227 , April 2010

On Reducing Cardiovascular Disease to a Rarity: Clinical Strategies and their Cost-Effectiveness

Received 18 August 2009

References 

  1. Peeters A, Nesselder W, McNeil J, Roon L, Boyko E, Tonkin A. Age-specific trends in cardiovascular mortality rates in Australia, Netherlands and USA since 1980. Eur Heart J. 2008;29(Abstract Supplement):762
  2. Access Economics Pty Ltd. The economic costs of a heart attack and chest pain (Acute Coronary Syndrome). http://www.accesseconomics.com.au/publicationsreports/reports.php.
  3. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand . Position statement on lipid management. Heart Lung Circ. 2005;14:275–291
  4. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118:576–585
  5. Probstfield JL. How cost-effective are new preventive strategies for cardiovascular disease?. Am J Cardiol. 2003;91:22G–27G
  6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Eng J Med. 2008;359:2195–2207
  7. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29:499–508
  8. Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland. Irish Med J. 2006;99:144–145
  9. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2:65–72
  10. National Institute for Clinical Excellence. Cardiovascular Risk Assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. www.nice.org.uk/CG67.
  11. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular risk. Lancet. 2003;361:717–725
  12. Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl. V):1–52
  13. Cholesterol Treatment Trialists’ Collaboration . Efficacy and safety of treatment; metanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  14. Daniels SR, Greer FR, the Committee on Nutrition . Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208
  15. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolaemia. Circulation. 2008;118:672–677
  16. Greenland P, LaBree L, Azer SP, Doherty TM, Detrano RC. Coronary artery calcification score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–215
  17. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. American Heart Association Scientific Statement. Assessment of coronary artery disease by cardiac computed tomography. Circulation. 2006;114:1161–1191
  18. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639
  19. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1.):49–57
  20. LaRosa JC, Grundy S, Kastelein J, Kostis J, Greten H. Safety and efficacy of atorvastatin-induced very low density lipoprotein levels in patients with coronary heart disease (a post-hoc analysis of the Treatment to New Targets (TNT) Study. Am J Cardiol. 2007;100:747–753
  21. Pedersen TR. Lipid guidelines—one for all?. Atherosclerosis. 2006;Suppl. 7:160;(abstract)
  22. Chen J, Campbell TC, Li J, Peto R. Diet, lifestyle and mortality in China. Oxford: Oxford University Press; 1990;
  23. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary heart disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563–569
  24. Appel LJ, Moore TJ, Oberzanek E for The DASH Collaborative Research Group. A clinical trial of the effect of dietary patterns on blood pressure. NEJM. 1997;336:1117–1124
  25. Statin Safety Task Force . Symposium: report of the national lipid association statin safety task force. Am J Cardiol. 2006;97(Suppl.):1C–97C

PII: S1443-9506(10)00004-1

doi: 10.1016/j.hlc.2010.01.002

Heart, Lung and Circulation
Volume 19, Issue 4 , Pages 225-227 , April 2010

Article Tools